# Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients

> **NCT05523661** · PHASE1 · UNKNOWN · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 15 (estimated)

## Conditions studied

- Ph Positive ALL
- CAR-T Cell
- Dasatinib

## Interventions

- **DRUG:** Dasatinib plus anti-CD19/CD22 CAR-T cells

## Key facts

- **NCT ID:** NCT05523661
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-01
- **Primary completion:** 2025-03-01
- **Final completion:** 2025-09-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2023-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05523661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05523661, "Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05523661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*